Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.35 |
| ▸ | CDK2 | P24941 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11998814 | 0.86 | CA1 (0.34) | CA1CA2MEN1KMT2ACYP1A2 | |
| SCHEMBL1332907 | 0.83 | HTR2A (0.37) | CA1CA2MEN1KMT2ACYP1A2 | |
| SCHEMBL15200385 | 0.80 | ALDH1A1 (0.37) | CA1CA2MEN1KMT2ACYP1A2 | |
| SCHEMBL29196807 | 0.80 | CA1 (0.35) | CA1CA2MEN1KMT2ACYP1A2 | |
| SCHEMBL12930022 | 0.79 | CYP2C9 (0.43) | CA1CA2MEN1KMT2ACYP1A2 | |
| SCHEMBL28924190 | 0.79 | MEN1 (0.36) | CA1CA2MEN1KMT2ACYP1A2 | |
| SCHEMBL18806835 | 0.78 | CA1 (0.37) | CA1CA2MEN1KMT2ACYP1A2 | |
| SCHEMBL18802300 | 0.78 | CA1 (0.37) | CA1CA2MEN1KMT2ACYP1A2 | |
| SCHEMBL30996356 | 0.78 | CA1 (0.38) | CA1CA2MEN1KMT2ACYP1A2 | |
| SCHEMBL26684224 | 0.77 | PTGS2 (0.38) | CA1CA2MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 620 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062361-A1 | PROCESS FOR THE PREPARATION OF BIO-BASED OLEFINS FROM PRIMARY ALCOHOL | BASF SE (DE) | 2026-03-05 | — | — | US | claimed |
| EP-4634171-A1 | PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE | F. Hoffmann-La Roche AG (CH) | 2025-10-22 | — | — | EP | claimed |
| US-20250313551-A1 | PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 2025-10-09 | — | — | US | claimed |
| US-20250197380-A1 | PHARMACEUTICAL INTERMEDIATE AND SYNTHESIS METHOD, AND ISOQUINOLINE DERIVATIVE AND SYNTHESIS METHOD THEREFOR | BANGENTAI(SHANDONG) BIOSCIENCES GROUP SHARE CO., LTD. (CN) | 2025-06-19 | — | — | US | claimed |
| WO-2025123046-A1 | SYNTHESIS OF LEUCINE-RICH REPEAT KINASE 2 MODULATORS | ARVINAS OPERATIONS, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| CN-119930599-A | Preparation process of high-purity azilsartan medoxomil | 山东鲁宁药业有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119731143-A | Process for the preparation of biobased olefins from primary alcohols | 巴斯夫欧洲公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119684209-A | Preparation method of seven-membered cyclic lysine monomer and copolyamide | 中国科学院长春应用化学研究所 | 2025-03-25 | — | — | CN | claimed |
| CN-115819412-B | Synthesis method and intermediate of N-heterocycle BET bromodomain inhibitor | 成都苑东生物制药股份有限公司 | 2025-03-14 | — | — | CN | claimed |
| US-12233402-B2 | Cross-coupling reaction catalysts, and methods of making and using same | YALE UNIVERSITY (US) | 2025-02-25 | — | — | US | claimed |
| US-9045462-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2015-06-02 | — | — | US | claimed |
| US-20140275570-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-8759544-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2014-06-24 | — | — | US | claimed |
| US-20140051866-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | claimed |
| US-20140051867-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | claimed |
| EP-2012779-B1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LAB (US) | 2012-05-16 | — | — | EP | claimed |
| US-7847104-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors | ABBOTT LABORATORIES (US) | 2010-12-07 | — | — | US | claimed |
| EP-2012779-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | Abbott Laboratories (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007121339-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2007-10-25 | — | — | WO | claimed |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | ABBVIE INC. | 2007-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | UTS2R, VIPR1, VRK1 | CA1 3426/4885CA2 1596/4885MEN1 2868/4885 |
| US-20140275570-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, SARS1, MAVS | CA1 4610/4885CA2 4724/4885MEN1 3345/4885 |
| US-20250197380-A1 | PHARMACEUTICAL INTERMEDIATE AND SYNTHESIS METHOD, AND ISOQUINOLINE DERIVATIVE AND SYNTHESIS METHOD THEREFOR | PARK7, SQLE, CYP4F11 | CA1 3270/4885CA2 4047/4885MEN1 1406/4885 |
| US-20140051867-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, SARS1, MAVS | CA1 4610/4885CA2 4724/4885MEN1 3345/4885 |
| US-20140051866-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, SARS1, MAVS | CA1 4595/4885CA2 4742/4885MEN1 3111/4885 |
| US-20260062361-A1 | PROCESS FOR THE PREPARATION OF BIO-BASED OLEFINS FROM PRIMARY ALCOHOL | ADH1C, ADH5, ADH1A | CA1 3019/4885CA2 3999/4885MEN1 3331/4885 |
| US-12233402-B2 | Cross-coupling reaction catalysts, and methods of making and using same | TET2, TIMCC, MDM4 | CA1 21/4885CA2 30/4885MEN1 696/4885 |
| US-20250313551-A1 | PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE | NQO2, SDHA, NDUFS3 | CA1 3931/4885CA2 3419/4885MEN1 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.